Polaryx Therapeutics, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $99.8M
- Price
- $2.00
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.25%
- Volume
- 135.3K
About
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Quick stats
Shares outstanding49.8M
Computed float12.5M
Float / shares25.1%
Cash runway (months)17.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002075320
Websitehttps://polaryx.com
AI Summary
AI-generated1/15
minorbullishexecutive change
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Polaryx Therapeutics appointed Dr. Will Charlton as Chief Medical Officer, bringing nearly two decades of experience in rare disease and pediatric drug development to the clinical-stage biotech.
Dr. Charlton previously served as SVP of Clinical Development at Tyra Biosciences and as CMO at Spruce Biosciences, where he focused on congenital adrenal hyperplasia and other rare genetic disorders.
The company remains on track to initiate the SOTERIA Phase 2 trial for its lead candidate PLX-200 in the fourth quarter of 2026, targeting multiple lysosomal storage disorders.